Clinical Trials Browser

Phase 1 × Recruiting × Hepatoblastoma × Clear all

Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT04897321 2026-04-15

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

CNSDermatologicGastrointestinalGenitourinarySarcoma

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04928677 2026-02-17

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Phase 1 Recruiting

50 enrolled

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Recurrence, Hepatoblastoma

NCT07148050 2026-02-17

IMPACT

Phase 1 Recruiting

21 enrolled

GastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Liposarcoma, Liver Neoplasms, Wilms Tumor, Rhabdomyosarcoma, Hepatoblastoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT06198296 2025-11-03

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Phase 1 Recruiting

21 enrolled

GastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Liposarcoma, Wilms Tumor, Rhabdomyosarcoma, Hepatoblastoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT04337177 2025-09-23

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Phase 1 Recruiting

20 enrolled

CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

Clinical Trials

NYMC195

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

IMPACT

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors